Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMSOB3U)

Drug Name

KH-CB19 Drug Info

Synonyms

KH CB19

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Investigative Drug(s)

Patented Agent(s)

Download the Complete Related Drug List

Drug(s) Targeting CDC-like kinase 3 (CLK3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
leucettine L41	DMBYND6	Discovery agent	N.A.	Investigative	[3]
------------------------------------------------------------------------------------

Drug(s) Targeting CDC-like kinase 1 (CLK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
TG003	DMP4HR2	Discovery agent	N.A.	Patented	[4]
leucettine L41	DMBYND6	Discovery agent	N.A.	Investigative	[3]
PMID23642479C17	DM4JWMA	Discovery agent	N.A.	Investigative	[5]
ML315	DMNOREK	Discovery agent	N.A.	Investigative	[5]
------------------------------------------------------------------------------------

Drug(s) Targeting Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Harmine	DMPA5WD	Discovery agent	N.A.	Patented	[6]
PMID28766366-Compound-Scheme21Left	DMWTRUK	N. A.	N. A.	Patented	[6]
PMID28766366-Compound-Scheme21Right	DMF3X40	N. A.	N. A.	Patented	[6]
PMID28766366-Compound-Scheme14BINDY	DMBQ0RN	N. A.	N. A.	Patented	[6]
TG003	DMP4HR2	Discovery agent	N.A.	Patented	[6]
PMID28766366-Compound-Scheme2WO2012/098065bottom	DMO4Q95	N. A.	N. A.	Patented	[6]
PMID28766366-Compound-Scheme16DMAT	DMQ5UEA	N. A.	N. A.	Patented	[6]
PMID28766366-Compound-Scheme7WO2012/098070upper	DMGAQR5	N. A.	N. A.	Patented	[6]
PMID28766366-Compound-Scheme9EHT1610	DMMZGC8	N. A.	N. A.	Patented	[6]
PMID28766366-Compound-Scheme9EHT5372	DM0O18N	N. A.	N. A.	Patented	[6]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
CDC-like kinase 1 (CLK1)	TTE6YDG	CLK1_HUMAN	Inhibitor	[2]
CDC-like kinase 3 (CLK3)	TTQPE1U	CLK3_HUMAN	Inhibitor	[2]
Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A)	TTSBVFO	DYR1A_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	Liver X receptors as regulators of macrophage inflammatory and metabolic pathways. Biochim Biophys Acta. 2011 Aug;1812(8):982-94.
2	Specific CLK inhibitors from a novel chemotype for regulation of alternative splicing. Chem Biol. 2011 Jan 28;18(1):67-76.
3	Leucettines, a class of potent inhibitors of cdc2-like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge leucettamine B: modulation of alternative pre-RNA splicing. J Med Chem. 2011 Jun 23;54(12):4172-86.
4	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.
5	Small-molecule pyrimidine inhibitors of the cdc2-like (Clk) and dual specificity tyrosine phosphorylation-regulated (Dyrk) kinases: development of chemical probe ML315. Bioorg Med Chem Lett. 2013 Jun15;23(12):3654-61.
6	Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.